Recent events
Recent events tied to this brand in public sources.
Back to profile9 entries
2026
Natco Pharma launches generic Carboplatin Injection in the US
Natco Pharma announced the launch of generic Carboplatin Injection in the US market through its subsidiary Natco Pharma USA LLC. The product was launched in manufacturing collaboration with Teyro Labs.
2022
NATCO completes acquisition of Dash Pharmaceuticals
NATCO Pharma Inc., a wholly owned subsidiary of NATCO Pharma Limited, completed its acquisition of Dash Pharmaceuticals LLC for US$18 million. Dash became a wholly owned subsidiary of NATCO Pharma Inc. and a step-down subsidiary of NATCO.
2021
NATCO launches Tipanat tablets in India
Natco Pharma launched Tipanat, a fixed-dose combination of trifluridine and tipiracil, in India as a bottle containing 20 tablets. The medicine is indicated for advanced colorectal and gastric cancer.
2021
Breckenridge launches 10 mg Everolimus tablets in the US
Natco Pharma said its marketing partner Breckenridge Pharmaceutical launched 10 mg Everolimus Tablets, a generic for Afinitor, in the US market. The drug is used to treat certain cancers.
2021
Natco Pharma Canada launches PrNAT-LENALIDOMIDE Capsules
Natco Pharma (Canada) announced the launch of PrNAT-LENALIDOMIDE Capsules, described as the first generic alternative to Revlimid approved by Health Canada.
2021
Natco and Lilly sign Baricitinib licensing agreement
Natco Pharma announced that it signed a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company to manufacture and commercialize Baricitinib for COVID-19 in India.
2020
NATCO launches Rivaroxaban under RPIGAT brand in India
Natco Pharma announced the launch of Rivaroxaban, an anticoagulant used to treat and prevent blood clots, under the RPIGAT brand in India. The product is available in four strengths.
2019
Natco launches Ibrunat in India
Natco Pharma launched Ibrunat, its own-brand cut-price version of the cancer drug ibrutinib, in India.
2019
NATCO Pharma completes investment in OMRV Hospitals
NATCO Pharma completed an investment of Rs.5 crore in OMRV Hospitals through a private placement of preference shares; it will hold 12.81% of OMRV Hospitals on a fully diluted basis.